Alder (United States)

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 10 of 16 papers

  • Open Access
  • Research Article
  • Citations11

Screening and evaluation of biomass upgrading strategies for sustainable transportation fuel production with biomass-derived volatile fatty acids

  • Oct 18, 2022
  • iScience
  • Jacob H Miller +15
  • Open Access
  • PDF
  • Book Chapter

Konstitueringen av en semiprofesjonell jentekorpraksis: En retrospektiv empirisk studie om frambringelsen av varige kulturelle verdier i et jentekor

  • Jan 01, 2022
  • Regine Vesterlid Strøm +1
  • Open Access
  • Preprint Article
  • Citations5

A female-specific role for Calcitonin Gene-Related Peptide (CGRP) in rodent pain models

  • Jun 02, 2021
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Candler Paige +13
  • Research Article
  • Citations1

Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2 (617)

  • Apr 14, 2020
  • Neurology
  • David W Dodick +7
  • Abstract
  • Citations1

PND80 RAPID MIGRAINE RESPONSE BY MONTH 1 AND CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MIGRAINE IN PHASE 3 TRIALS OF EPTINEZUMAB

  • May 01, 2019
  • Value in Health
  • S.j Tepper +5
  • Research Article
  • Citations2

Early Impact of Eptinezumab on the Health-Related Quality of Life (HRQoL) of Patients with Episodic or Chronic Migraine: SF-36 Analysis Across the Spectrum of Migraine (P1.10-025)

  • Apr 09, 2019
  • Neurology
  • Merle Diamond +5
  • Research Article
  • Citations10

Bioanalytical challenges and unique considerations to support pharmacokinetic characterization of bispecific biotherapeutics.

  • Mar 01, 2019
  • Bioanalysis
  • Mark Ma +8
  • Research Article
  • Citations2

Eptinezumab Achieved Meaningful Reductions in Migraine Activity Within 24 Hours That Were Sustained Through Week 12: Results From PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Phase 3 Trial (P4.092)

  • Apr 10, 2018
  • Neurology
  • Timothy Smith +5
  • Research Article
  • Citations395

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

  • Oct 05, 2014
  • The Lancet Neurology
  • David W Dodick +12
  • Open Access
  • Conference Article
  • Citations28

Verification of C Programs Using Automated Reasoning

  • Sep 01, 2007
  • David Crocker +1
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.